Publications by authors named "Merav Bar"

Claim this Profile
N
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop, Merav Bar, Pere Barba

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma.
Roni Shouval, Christopher Strouse, Soyoung Kim, Temitope Oloyede, Sairah Ahmed, Merav Bar, Pere Barba

Transplant Cell Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
Francesco Mazziotta, Lauren E Martin, Daniel N Egan, Merav Bar, Sinéad Kinsella

Nat Commun· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.
Steven J Siegel, Susan DeWolf, Joseph Schmalz, Wael Saber, Jiayi Dong, Merav Bar

medRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-Blood Longitudinal Molecular Profiling Maps the Road of Graft Versus Host Disease (GVHD).
Merav Bar, Mohammed El Anbari, Darawan Rinchai, Mohammed Toufiq, Dhanya Kizhakayil

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.
Francesco Mazziotta, Lauren E Martin, Daniel N Eagan, Merav Bar, Sinéad Kinsella

medRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.
Albert Oriol, Roman Hájek, Ivan Spicka, Irwindeep Sandhu, Yael C Cohen, Merav Bar

Clin Lymphoma Myeloma Leuk· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Elizabeth F Krakow, Michelle Brault, Corinne Summers, Tanya M Cunningham, Melinda A Biernacki, Merav Bar

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis.
Brian Kiesel, Mayu Osawa, Madhan Masilamani, Merav Bar, Kevin Hsu

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Krishna R Juluri, Qian Vicky Wu, Jenna Voutsinas, Jue Hou, Alexandre V Hirayama, Merav Bar

Blood Adv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Miranda C Lahman, Thomas M Schmitt, Kelly G Paulson, Nathalie Vigneron, Denise Buenrostro, Merav Bar

Sci Transl Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, Mahmoud Aljurf, Taiga Nishihori, Merav Bar

Transplant Cell Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
Carla S Walti, Elizabeth M Krantz, Joyce Maalouf, Jim Boonyaratanakornkit, Jacob Keane-Candib, Merav Bar

JCI Insight· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Jordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, Salvatore Fiorenza, Alyssa Sheih, Barbara S Pender, Merav Bar

Blood· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up issues in survivors of hematologic malignancies - Current stance and future perspectives.
Ibrahim N Muhsen, Merav Bar, Bipin N Savani, Elihu H Estey, Shahrukh K Hashmi

Blood Rev· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Merav Bar, Susan M Ott, E Michael Lewiecki, Kyriakie Sarafoglou, Joy Y Wu

Biol Blood Marrow Transplant· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life.
George E Georges, Merav Bar, Lynn Onstad, Jean C Yi, Mazyar Shadman

Biol Blood Marrow Transplant· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Ana Cordeiro, Evandro D Bezerra, Alexandre V Hirayama, Joshua A Hill, Qian V Wu, Merav Bar

Biol Blood Marrow Transplant· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
Julia Ruark, Erin Mullane, Nancy Cleary, Ana Cordeiro, Evandro D Bezerra, Merav Bar

Biol Blood Marrow Transplant· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Tania Jain, Merav Bar, Ankit J Kansagra, Elise A Chong, Shahrukh K Hashmi

Biol Blood Marrow Transplant· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Ankit J Kansagra, Noelle V Frey, Merav Bar, Theodore W Laetsch, Paul A Carpenter, John A Barrett

Bone Marrow Transplant· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.
Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E Woolfrey, Merav Bar

Blood Adv· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
Joshua A Hill, Elizabeth M Krantz, Kevin A Hay, Sayan Dasgupta, Terry Stevens-Ayers, Merav Bar

Blood Adv· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients.
Yoshihiro Inamoto, Jennifer White, Reiko Ito, Paul J Martin, Giancarlo Fatobene, Merav Bar

Blood Adv· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Aude G Chapuis, Daniel N Egan, Merav Bar, Thomas M Schmitt, Megan S McAfee

Nat Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis